MOSCOW, 7 Mar – RIA Novosti. The European Union could lose about 100 billion euros due to investor concerns about the “sluggish” pace of vaccinations, writes Bloomberg.
As the agency notes, the fight against coronavirus in Europe is going slower than expected, and this, in turn, leads to a delay in economic recovery and slows down the work of business. The delay in resuming these processes, it is reported, could cost the European Union between 50 and 100 billion euros.
In addition, investors are concerned about the increase in the incidence of COVID-19 in the EU, as the development of this trend could disrupt their strategies, Bloomberg adds, citing statements by the BlackRock Investment fund and the financial conglomerate Bank of America. Also, European funds are worried about capital outflows, which, as follows from the material, are recorded in the region for the third week in a row.
“Europe needs to accelerate the pace of vaccine introduction if it wants to defeat the virus. <...> At the same time, the process (vaccination – Ed.) Is hampered by bureaucracy and contradictory statements by the authorities,” the agency quotes the chief strategist of the Principal Global Investors Fund Simu Shah.
The European Commission has contracted the opportunity to buy for the countries of the region about 2.3 billion doses of vaccines against coronavirus at the stage of their development. The population of the EU is about 450 million.
So far, the European Union has centrally approved the use of three drugs, with the manufacturing companies of which preliminary contracts were previously signed. However, in the first months of vaccination, the countries of the union faced undersupply of doses of some drugs compared to contractual expectations.